Allergan Plc is on course to defeat a non-binding shareholder resolution tabled by David Tepper’s hedge fund Appaloosa LP that would have instructed the drugmaker’s CEO Brent Saunders to immediately give up his role as chairman, people familiar with the matter said.

Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Allergan Plc’s experimental add-on treatment for depression failed three late-stage studies, casting doubts over the company’s drug pipeline and sending the Botox maker’s shares down nearly 4 percent.

Bristol-Myers Squibb Co.’s top shareholder Wellington Management does not support the U.S. drugmaker’s $74 billion deal to buy biotech Celgene Corp., imperiling what would be the largest pharmaceutical acquisition of all time.

Biotech investing is a volatile business as 2018 has seen a little-known hedge fund with a focus on biotech and the life sciences beat out a couple of heavy hitters, David Einhorn and Bill Ackman.

A Bay Area hedge fund has filed a lawsuit against embattled Theranos alleging the company duped investors about the efficacy of its products in order to attract investments of nearly $100 million.

Democratic lawmakers on Monday attacked “massive” price increases of two heart drugs by Canada’s Valeant, fueling a rout in drugmaker shares on worries of a government and insurer clampdown on […]

Hedge fund manager Kyle Bass has been given the green light to try to profit from efforts to wipe out drug patents, a move that could fuel similar strategies by […]